Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
- PMID: 17369375
- PMCID: PMC1856849
- DOI: 10.1136/gut.2005.088732
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
Abstract
The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. It has been shown by many studies that the long-term outcome of these diseases is not influenced by standard treatments and that the need for surgery is not decreasing in this population over the years. There is recent evidence that with immunosuppression and treatment with infliximab long-term healing of the bowel can be achieved and that this affects the outcome of both Crohn's disease and ulcerative colitis. We propose that future studies should focus on healing and disease course as primary outcome measures.
Conflict of interest statement
Competing interests: None.
References
-
- Modigliani R, Mary J Y, Simon J F.et al Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 199098811–818. - PubMed
-
- D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo‐) colitis with azathioprine. Gastrointest Endosc 199950667–671. - PubMed
-
- Lemann M, Mary J Y, Colombel J F.et al A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology 20051281812–1818. - PubMed
-
- D'Haens G, Geboes K, Ponette E.et al Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 19971121475–1481. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources